October 23, 2009
Phase 3 study of Nexavar for the treatment of non-responsive thyroid cancer
Nexavar is a multikinase inhibitor that targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation and angiogenesis. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.
Nexavar is already indicated for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma.
For more information call (800) 288-8371 or visit www.nexavar.com.